Robert Langer is an acclaimed chemical engineer, professor, and investor in biomedical technology. He is one of 10 Institute Professors at MIT, which is the highest honor that can be awarded to a faculty member. He has written more than 1,500 articles, with 1,400 patents issued and pending worldwide that have been licensed to over 400 companies. He is the most cited engineer in history with an H-index of 283 and over 331,000 citations according to Google Scholar. His inventions are estimated to have affected over 2 billion lives, and his most recent public work involves the coronavirus vaccine created by Moderna, which is the biotech company he co-founded.
In this interview, Arjun, Michael, and Tiger discuss with Prof. Langer his early career struggles as a freshly minted graduate student, his groundbreaking postdoc research on blood vessel growth for Judah Folkman that few believed could become reality, the future of tissue engineering technology, why the mRNA vaccine is safe and has withstood the test of time, the success of Langer Lab in spurring dozens of biotech companies, and the future of medicine amongst many other topics.
Prof. Langer was first offered 20 traditional chemical engineering jobs after he graduated from Cornell’s PhD program. Instead of taking those offers, however, he fought an uphill battle to find a position in medical research, eventually working with Judah Folkman at the Boston Children’s Hospital. Prof. Langer recalls that he didn't know too much biology about chemistry in his early career, so a lot of times he felt he was in the dark.
For the years that Prof. Langer has run his lab, the Langer Lab, he and his team have focused on two broad areas in biomedical engineering: tissue engineering and drug delivery systems. Both research areas lie at the core of many modern medical revolutions, from advanced drugs to synthetic organs.
Another drug delivery breakthrough that Prof. Langer describes more in-depth are star-shaped pills. The guiding principle behind the design is the following: standard pills are only able to deliver their encapsulated drug for a day. There are more crude ways to design pills that can administer drugs for longer periods, but the bulkier design could cause harm to the host, or block part of the digestive system. The star-shaped design solves for this: it is a pill that is small when ingested, expands inside the body, and leaves a large hole in its center for the digestive track to act normally. This kind of pill would make delivering some drugs, like insulin, much easier.
Prof. Langer then goes on to describe some of the broader aspects of these research fields. What are the most promising future applications for tissue engineering and drug delivery research? What are the current obstacles/limitations in research for tissue engineering and drug delivery systems? What capacity does AI have to further push the frontier in research for these fields?
Prof. Langer attributes two reasons to the amazing speed of the mRNA vaccine development process: the superior nature of the technology itself in comparison to previous vaccinat technologies, and the U.S. government’s “Operation Warp Speed” that invested a lot of capital into the private sector while providing regulatory support.
He explains the mRNA vaccine to us: DNA makes RNA, and RNA makes protein. While classically people focused on the protein part when producing vaccines, the process takes too long, and Moderna directly started with the mRNA part. The beauty of mRNA is that one can make it very quickly, give it to the body, and start testing for efficacy.
A key pillar of the mRNA vaccine technology is drug delivery, however. To a patient, the mRNA would get destroyed immediately if not properly encapsulated and protected by nanoparticles when being injected into the body. But once it’s successfully injected into the muscle, mRNA will trigger the body to start making antibodies and immunize the patient.